An official website of the United States government
Home
Name
hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor MK-6482
Alternate Names
None
Abbreviations
None
Category
Chemotherapy
Subcategory
None
NSC Number
None
Primary Site
Kidney
Histology
Remarks
July 2020: The hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor MK-6482, a novel investigational candidate, received Breakthrough Designation from FDA for the treatment of patients with von Hippel-Lindau disease-associated renal cell carcinoma with non-metastatic RCC tumors less than three centimeters in size, unless immediate surgery is required.
Coding
This drug should be coded
